Goldman Sachs Group Inc. Decreases Stock Holdings in Urogen Pharma $URGN

Key Points

• Goldman Sachs Group Inc. has reduced its stake in Urogen Pharma by 10.5%, selling 33,188 shares during the first quarter, leaving it with 284,334 shares valued at about $3.15 million.
• Urogen Pharma reported a loss of ($1.05) earnings per share for its recent quarter, missing analyst expectations of ($0.82), while revenues slightly exceeded forecasts at $24.22 million.
• Urogen Pharma's stock has experienced a decline of 4.9% and is currently trading at $17.95, with a twelve-month range between $3.42 and $21.71.

Goldman Sachs Group Inc. decreased its position in Urogen Pharma (NASDAQ:URGN - Free Report) by 10.5% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 284,334 shares of the company's stock after selling 33,188 shares during the period. Goldman Sachs Group Inc. owned 0.62% of Urogen Pharma worth $3,145,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in URGN. CWM LLC increased its stake in Urogen Pharma by 6,047.1% in the 1st quarter. CWM LLC now owns 5,225 shares of the company's stock valued at $58,000 after buying an additional 5,140 shares during the last quarter. Lazard Asset Management LLC purchased a new stake in Urogen Pharma in the 4th quarter valued at about $67,000. GAMMA Investing LLC increased its stake in Urogen Pharma by 6,908.4% in the 1st quarter. GAMMA Investing LLC now owns 7,499 shares of the company's stock valued at $83,000 after buying an additional 7,392 shares during the last quarter. ProShare Advisors LLC purchased a new stake in Urogen Pharma in the 4th quarter valued at about $137,000. Finally, Janus Henderson Group PLC purchased a new stake in Urogen Pharma in the 4th quarter valued at about $149,000. Hedge funds and other institutional investors own 91.29% of the company's stock.

Insider Transactions at Urogen Pharma

In other Urogen Pharma news, General Counsel Jason Drew Smith sold 7,522 shares of the business's stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $19.14, for a total value of $143,971.08. Following the transaction, the general counsel owned 41,492 shares in the company, valued at approximately $794,156.88. The trade was a 15.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Mark Schoenberg sold 10,000 shares of the business's stock in a transaction dated Monday, August 11th. The shares were sold at an average price of $17.69, for a total transaction of $176,900.00. Following the completion of the transaction, the insider owned 148,229 shares in the company, valued at $2,622,171.01. The trade was a 6.32% decrease in their position. The disclosure for this sale can be found here. Insiders sold 25,062 shares of company stock worth $465,115 in the last 90 days. Corporate insiders own 4.70% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Scotiabank reiterated an "outperform" rating on shares of Urogen Pharma in a research note on Friday, June 13th. The Goldman Sachs Group set a $16.00 price target on shares of Urogen Pharma and gave the stock a "neutral" rating in a research note on Friday, June 13th. D. Boral Capital restated a "buy" rating and set a $25.00 price target on shares of Urogen Pharma in a research note on Tuesday, August 5th. Piper Sandler assumed coverage on shares of Urogen Pharma in a research note on Monday, August 18th. They set an "overweight" rating and a $36.00 price target for the company. Finally, Wall Street Zen upgraded shares of Urogen Pharma from a "sell" rating to a "hold" rating in a research note on Saturday, September 13th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, Urogen Pharma has an average rating of "Buy" and a consensus target price of $32.00.

Urogen Pharma Trading Up 0.6%

Shares of Urogen Pharma stock traded up $0.10 on Tuesday, hitting $18.09. 51,556 shares of the company traded hands, compared to its average volume of 1,505,308. The firm's 50-day simple moving average is $18.69 and its 200 day simple moving average is $13.26. The company has a market cap of $836.84 million, a P/E ratio of -5.45 and a beta of 1.10. Urogen Pharma has a 12-month low of $3.42 and a 12-month high of $21.71.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported ($1.05) EPS for the quarter, missing analysts' consensus estimates of ($0.82) by ($0.23). The business had revenue of $24.22 million during the quarter, compared to analysts' expectations of $23.06 million. Urogen Pharma had a negative return on equity of 97,487.15% and a negative net margin of 164.44%. Analysts predict that Urogen Pharma will post -3.12 earnings per share for the current year.

Urogen Pharma Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.